Abramson Cancer Center at Penn Medicine: all 457 studies

Page 4 of 5. Open to participants first (84), then studies with results posted, then the rest; newest registration first within each.

• Bio-marker Analysis Using Circulating Tumor Cells in Patients With MelanomaWithdrawnNCT02828345
• The Breast Program - Translational Cancer ResourceActive, not recruitingNCT02798341
• Physician-Patient Communication and Expectations Regarding Ovarian Cancer PrognosisTerminatedNCT02769546
• Cardiotoxicity of Radiation Therapy (CTRT)CompletedNCT02769299
• A Non-Invasive Cervical Cancer Screening Modality: A Pilot StudyTerminatedNCT02767726Not applicable
• Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation OncologyCompletedNCT02756767
• Adherence to Aromatase Inhibitors: The Role of PartnersCompletedNCT02753985
• FDG PET/CT in Lung Cancer StagingCompletedNCT02738398Not applicable
• Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the LiverCompletedNCT02724540Phase 2
• Early FDG PET in MelanomaTerminatedNCT02716077Not applicable
• C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate CancerCompletedNCT02715583Early Phase 1
• PDT Plus Vitamin D3 for Anal DysplasiaWithdrawnNCT02698293Phase 1
• Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial CancerTerminatedNCT02665962Not applicable
• Optional Sub-study to Intraoperative Imaging With ICG RegistryCompletedNCT02651246
• Intraoperative Imaging With ICG RegistryCompletedNCT02640170
• Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersCompletedNCT02639026Phase 1
• Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CTActive, not recruitingNCT02637934Phase 1
• Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 TherapyTerminatedNCT02608528
• Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium TrialActive, not recruitingNCT02603341Not applicable
• A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast CancerCompletedNCT02599363Phase 1
• Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic CarcinomaCompletedNCT02588443Phase 1
• Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical StimulationCompletedNCT02559401
• PAIN-LESS: Understanding and Alleviating Pain for Cancer Patients in Academic and Community HospitalsCompletedNCT02559375
• Study on Breast Cancer Patient Perspectives of ExerciseCompletedNCT02559362
• Gut Microbiota And RadiotherapyCompletedNCT02559349
• LIVESTRONG Survivorship Care Plan: Continued Data Collection and Follow Up SurveyCompletedNCT02559323
• Smart Adult Living After Childhood Cancer (SmartALACC) Online Care Plans: Feasibility and Patient SatisfactionCompletedNCT02559219
• Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of CareCompletedNCT02558998Not applicable
• CTCs for High Grade GliomaCompletedNCT02558335
• Functional Outcome Measures for Head and Neck PatientsTerminatedNCT02530112
• Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast CancerActive, not recruitingNCT02530008
• WISER After Ovarian Cancer - Exercise Pilot StudyCompletedNCT02529150Not applicable
• A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic ServicesCompletedNCT02517554
• Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal StudyCompletedNCT02514499Not applicable
• Assessment of Cancer Concerns at the End of Treatment (ACE)CompletedNCT02514486
• Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate CancerCompletedNCT02479945Not applicable
• Palliative Care Outcomes in the Management of Malignant Ascites by Interventional RadiologyWithdrawnNCT02477657
• FDG-PET/CT Imaging as Early Predictor of DPCompletedNCT02476734
• Dietary Flaxseed in NSCLCTerminatedNCT02475330Phase 2
• Mechanisms and Predictors of Unusual Radiation or Chemotherapy ToxicityWithdrawnNCT02469194
• Autologous OC-L Vaccine and Ovarian CancerTerminatedNCT02452775Phase 1
• Evaluating Therapeutic Response to Novo-TTFCompletedNCT02441322Not applicable
• The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung CancerCompletedNCT02380196
• A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)CompletedNCT02363829Phase 1
• IFN-DLI for Relapsed Acute Leukemia After Allo-SCTCompletedNCT02331706Early Phase 1
• Healthy Human Control Blood Collection for Validation of Biomarker AssayCompletedNCT02302885
• A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal CancerWithdrawnNCT02277392Phase 1
• Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant MelanomaCompletedNCT02257424Phase 1/2
• Exercise and Colon CancerCompletedNCT02250053Not applicable
• Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer CohortsCompletedNCT02246738
• Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)CompletedNCT02233504Early Phase 1
• Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid TumorsCompletedNCT02225002Phase 1
• Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal CancerActive, not recruitingNCT02213497Phase 1
• A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic CancerActive, not recruitingNCT02207465Phase 1
• Study of Efficacy and Safety of CTL019 in Adult ALL PatientsWithdrawnNCT02167360Phase 2
• Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic DiseasesActive, not recruitingNCT02159742
• Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid TumorsCompletedNCT02157831Early Phase 1
• Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural MesotheliomaActive, not recruitingNCT02153229Phase 2
• Patient-Centered Acupuncture for Pain (PCAP)CompletedNCT02152020
• Acupuncture Feasibility Trial for Dyspnea in Lung CancerCompletedNCT02094950Phase 1
• DC Vaccine for Patients With Ductal Carcinoma In SituCompletedNCT02061332Phase 1/2
• A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic CancerCompletedNCT02030860Phase 1
• Yoga for Breast CancerCompletedNCT01985945Not applicable
• Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood SamplesCompletedNCT01985919
• HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck CancerCompletedNCT01984359Not applicable
• Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMMCompletedNCT01958528
• TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC PatientsActive, not recruitingNCT01918683Not applicable
• A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant MelanomaCompletedNCT01897116Phase 1
• Proton Therapy for High Risk Prostate CancerWithdrawnNCT01811810Not applicable
• Multiple Myeloma and ExerciseCompletedNCT01809717Not applicable
• Intraoperative Imaging of Breast Cancer With Indocyanine GreenCompletedNCT01796041Early Phase 1
• A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center StudyCompletedNCT01736345
• HPPH and PDT for Pleural MalignancyCompletedNCT01673074Phase 1
• A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. ProstatectomyCompletedNCT01661166Phase 4
• Multi-peptide Vaccine With Basilixumab for Breast CancerCompletedNCT01660529Early Phase 1
• Dovitinib in Neuroendocrine TumorsCompletedNCT01635907Phase 2
• CRLX101 Plus Bevacizumab in Advanced RCCCompletedNCT01625936Phase 1
• Autophagy Induction After Bortezomib for MyelomaCompletedNCT01594242Early Phase 1
• Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following ProstatectomyCompletedNCT01548807Phase 1
• Does Cryofixation of Skin Specimens Affect Quality of Subsequent Formalin Fixed Paraffin Embedded H and E HistologyCompletedNCT01540695
• MLN8237 in Head and Neck CancerCompletedNCT01540682Phase 1
• Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell CarcinomaCompletedNCT01510119Phase 1/2
• A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic CancerCompletedNCT01506973Phase 1/2
• BETERNet Notch Signaling and Novel Biomarkers for Barretts EsophagusCompletedNCT01484925
• Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic CarcinomaCompletedNCT01456585Phase 1
• Experience of Non-Melanoma Skin Cancer (NMSC) Mohs Surgery ProjectCompletedNCT01452984
• DCE-MRI PET Bevacizumab Study in Rectal CancerWithdrawnNCT01426074Phase 2
• Cyclophosphamide and Pulse Dexamethasone With Rapamycin or HydroxychloroquineCompletedNCT01396200Early Phase 1
• DIBH Proton PlanningCompletedNCT01386697
• Pelvic Floor Disorders in Survivors of Gynecologic MalignanciesCompletedNCT01370122
• Cardiovascular Effects of Sunitinib Therapy (CREST)CompletedNCT01370109
• Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate CancerActive, not recruitingNCT01352429
• PD0332991/Paclitaxel in Advanced Breast CancerCompletedNCT01320592Phase 1
• Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian CancerTerminatedNCT01312376Phase 1
• The Effects of Radiation in Reconstructed BreastsCompletedNCT01292772
• Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)CompletedNCT01221506Early Phase 1
• Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) StudyCompletedNCT01212731
• Intrapleural Gene Transfer for Pleural MesotheliomaCompletedNCT01212367Phase 1
• FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal CancerCompletedNCT01206530Phase 1/2
• BCRL Prevention PilotCompletedNCT01166672

← Abramson Cancer Center at Penn Medicine overview and focus areas